Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Lotronex Formulary Kit Faulted For Implied Claims Beyond Studies

Executive Summary

Glaxo Wellcome Lotronex marketing materials "contain unsubstantiated Health-Related Quality of Life, productivity and economic claims" not adequately supported by clinical studies, FDA charged in an April 28 letter from the agency's Division of Drug Marketing, Advertising & Communications.

You may also be interested in...



Zelmac Cost Analysis Data Could Define Use - Committee Member

Maintenance studies for Novartis' Zelmac should include a cost analysis component, FDA Gastrointestinal Drugs Advisory Committee member Michael Wolfe, MD, said June 26.

Zelmac Cost Analysis Data Could Define Use - Committee Member

Maintenance studies for Novartis' Zelmac should include a cost analysis component, FDA Gastrointestinal Drugs Advisory Committee member Michael Wolfe, MD, said June 26.

Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics

Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel